etwork Pharmacology Dissection of Multiscale Mechanisms for Jiaoqi Powder in Treating Ulcerative Colitis

Phase 1

Recruiting

Conditions: lcerative colitis

Registration Number: ITMCTR2100004421

Lead Sponsor: Department of Gastroenterology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, No.16 of Road Airport, Baiyun district, Guangzhou 510405, Province Guangdong, China

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: Not specified

Inclusion Criteria

The diagnosis of UC is based on the clinical manifestations, characteristic endoscopic and histopathological changes, and the exclusion of infectious bowel disease:
(1) The clinical manifestations are recurrent or persistent abdominal pain, diarrhea, tenesmus, mucus pus and blood in the stool, fever, fatigue and other systemic symptoms of varying degrees, and may have extraintestinal manifestations such as skin, mucous membranes, joints, eyes, liver and gallbladder. The course of the disease is more than 4-6 weeks.
(2) The characteristic manifestations under endoscopy are persistent and confluent colitis and rectal involvement. The texture of mucosal blood vessels is blurred, disordered or disappeared. In severe cases, mucosal texture, spontaneous bleeding and ulcer formation can be seen.
(3) Mucosal pathology examination: pathologically visible structural changes (crypt bifurcation, crypt structural deformation, crypt atrophy and surface irregularity), epithelial abnormalities (mucin depletion and Paneth cell metaplasia) and inflammatory response manifestations (Inflammatory cells in the lamina propria increased, basal plasma cells increased, lymphocytes increased, and lamina propria eosinophils increased).
(4) Exclude bacterial infectious enteritis, amoebic enteropathy, intestinal schistosomiasis, intestinal tuberculosis, fungal enteritis, human immunodeficiency virus infection, ischemic enteropathy, eosinophilic enteritis, Behcet's disease, etc. disease.
(5) Age 18-75 years old. The patient informed consent and was willing to receive corresponding treatment.

Exclusion Criteria

(1) Typical medical history, no report of colonoscopy, no histological evidence or uncertain histological examination. (2) Patients with abdominal pain, diarrhea, mucus, pus and blood in the stool due to organic diseases or with any other diseases that can explain the above clinical symptoms.
(3) Although ulcerative colitis is the first diagnosis, but other infectious or non-infectious colitis at the same time, or accompanied by serious surgical diseases such as toxic megacolon, intestinal obstruction, intussusception, intestinal bleeding Necrosis, stenosis, perforation, cancer, etc.
(4) Patients with a history of abdominal surgery, patients with a history of abdominal surgery, organic diseases of the digestive system (such as chronic pancreatitis, cirrhosis, etc.), or systemic diseases (such as hyperthyroidism, diabetes, chronic renal insufficiency, etc.).
(5) People who are unconscious, dementia, various mental illnesses, severe neurosis and unwilling to cooperate.
(6) Severe primary cardiovascular disease, liver disease, kidney disease, hematological disease, lung disease, autoimmune system disease, or serious disease that affects their survival, such as tumor or AIDS.
(7) Pregnant and lactating women.
(8) People with allergies or allergies to multiple drugs.
(9) Those who are allergic to the components of Chinese medicine; those who are participating in clinical trials of other drugs within 4 weeks.
(10) There are cognitive or other impairments (such as vision, etc.) that affect the participants to complete the self-report.
(11) Those who refuse to carry out drug elution.
(12) The investigator has good reason to believe that the participants current medical or psychological state is not suitable for the research.